Search research articles
Contact Us
Filters
Showing results (81-90 of 157) with videos related to
Page
of 16
Sort By:
Journal of Diabetes
|
April 15, 2018
American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia
Zachary Bloomgarden, Daniel Einhorn, Yehuda Handelsman, et al.
Diabetes, Obesity & Metabolism
|
December 1, 2018
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
Yehuda Handelsman, Chantal Mathieu, Stefano Del Prato, et al.
Diabetes Care
|
October 9, 2012
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, et al.
Journal of Diabetes
|
October 7, 2010
Good news!
Zachary T Bloomgarden, Guang Ning, Andrew J Drexler, et al.
JAMA
|
July 4, 2017
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial
Carol Wysham, Anuj Bhargava, Louis Chaykin, et al.
Diabetes, Obesity & Metabolism
|
February 17, 2017
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II
Lawrence A Leiter, José Luis Zamorano, Maja Bujas-Bobanovic, et al.
Journal of Diabetes and Its Complications
|
January 3, 2019
Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes
Yehuda Handelsman, Christina Chovanes, Terry Dex, et al.
Diabetes, Obesity & Metabolism
|
July 6, 2018
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
Julio Rosenstock, Yehuda Handelsman, Josep Vidal, et al.
Expert Review of Cardiovascular Therapy
|
July 25, 2022
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements
Michael Miller, Lale Tokgozoglu, Klaus G Parhofer, et al.
European Heart Journal
|
March 31, 2026
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Muhammad Shahzeb Khan, Muhammad Hamza Dawood, Yehuda Handelsman, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 157) with videos related to
Sort By:
Page
of 16
Journal of Diabetes
|
April 15, 2018
American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia
Zachary Bloomgarden, Daniel Einhorn, Yehuda Handelsman, et al.
Diabetes, Obesity & Metabolism
|
December 1, 2018
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
Yehuda Handelsman, Chantal Mathieu, Stefano Del Prato, et al.
Diabetes Care
|
October 9, 2012
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, et al.
Journal of Diabetes
|
October 7, 2010
Good news!
Zachary T Bloomgarden, Guang Ning, Andrew J Drexler, et al.
JAMA
|
July 4, 2017
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial
Carol Wysham, Anuj Bhargava, Louis Chaykin, et al.
Diabetes, Obesity & Metabolism
|
February 17, 2017
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II
Lawrence A Leiter, José Luis Zamorano, Maja Bujas-Bobanovic, et al.
Journal of Diabetes and Its Complications
|
January 3, 2019
Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes
Yehuda Handelsman, Christina Chovanes, Terry Dex, et al.
Diabetes, Obesity & Metabolism
|
July 6, 2018
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
Julio Rosenstock, Yehuda Handelsman, Josep Vidal, et al.
Expert Review of Cardiovascular Therapy
|
July 25, 2022
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements
Michael Miller, Lale Tokgozoglu, Klaus G Parhofer, et al.
European Heart Journal
|
March 31, 2026
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Muhammad Shahzeb Khan, Muhammad Hamza Dawood, Yehuda Handelsman, et al.
Page
of 16